Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Breakthrough bladder cancer therapy shows benefits in trial

Breakthrough bladder cancer therapy shows benefits in trial

27th November 2014

A new breakthrough therapy for advanced bladder cancer has demonstrated its potential benefits in an early-stage trial.

Evaluated by Queen Mary University of London, the antibody functions by blocking a protein called PD-L1 that is thought to help cancer cells evade immune detection. It was originally developed by Roche under the name MPDL3280A.

In a phase I trial, 68 patients with advanced bladder cancer who had failed other standard treatments such as chemotherapy received the drug, with 43 percent of PD-L1-positive patients seeing their tumours shrink after six weeks of treatment.

This rose to 52 percent after 12 weeks of follow-up. In two of these patients, radiological imaging found no evidence of the cancer at all following the treatment. Larger trials are now needed to confirm these findings.

Lead author Dr Tom Powles, consultant medical oncologist at Barts Cancer Institute at Queen Mary University of London, said: "We hope to fast-track this process so we can begin to give hope to the thousands of people affected by advanced bladder cancer each year."

About 10,000 people are diagnosed with bladder cancer in the UK every year, with men generally more susceptible than women. There have been no major treatment advances for this condition in the past 30 years.ADNFCR-8000103-ID-801762851-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.